Clinical Trials Browser

INDUSTRY × Lymphoma, B-Cell × Bendamustine Hydrochloride × Clear all

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, B-Cell

NCT05023980 2026-01-22

BRUIN CLL-313

Phase 3 Active not recruiting

309 enrolled

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03424122 2025-08-21

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Phase 1 Completed

50 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04792489 2025-04-24

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2 Recruiting

248 enrolled

CNSLymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Lymphoma, Mantle-Cell

NCT04666038 2025-04-20

BRUIN CLL-321

Phase 3 Active not recruiting

238 enrolled 17 charts 1 FDA

LymphoidOther hematologic neoplasm

Hematologic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04023071 2023-10-26

FT516 in Subjects With Advanced Hematologic Malignancies

Phase 1 Terminated

72 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Myeloid, Acute, Lymphoma, B-Cell

NCT04245722 2023-10-26

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Phase 1 Terminated

98 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT04882163 2021-10-05

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, B-Cell

Clinical Trials

FT819 in Subjects With B-cell Malignancies

BRUIN CLL-313

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

DALY II USA/ MB-CART2019.1 for DLBCL

BRUIN CLL-321

FT516 in Subjects With Advanced Hematologic Malignancies

FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma